Mucosal immunisation with novel Streptococcus pneumoniae protein antigens enhances bacterial clearance in an acute mouse lung infection model

FEMS Immunology and Medical Microbiology

Volumn 44, Issue 1, 2005, Pages 59-67

  Jomaa, Maha ^a,b   Kyd, Jennelle M ^a   Cripps, Allan W ^a,c  

^a UNIVERSITY OF CANBERRA   (Australia)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c GRIFFITH UNIVERSITY   (Australia)

Author keywords

Mucosal; Pneumococcal; Protein; Vaccine

Indexed keywords

ALANYLLEUCYLASPARAGINYLISOLEUCYLGLUTAMYLASPARAGINYLISOLEUCYLISOLEUCYL ALANYLGLUTAMYLISOLEUCYLLYSYLGLUTAMYLALANYLSERINE; ANTIBODY; ARGINYLISOLEUCYLISOLEUCYLLYSYLPHENYLALANYLVALYLTYROSYLALANYLLYSINE; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; PNEUMOCOCCUS VACCINE; RIBOSOME PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DISEASE MODEL; DRUG ISOLATION; DRUG PURIFICATION; ELUTION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INOCULATION; INTESTINE; ISOLATION PROCEDURE; LUNG CLEARANCE; LUNG INFECTION; MALE; MOLECULAR WEIGHT; MOUSE; MUCOSA; NONHUMAN; PEYER PATCH; PHAGOCYTE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN ISOLATION; PROTEIN PURIFICATION; PROVOCATION TEST; SEROTYPE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; TIME;

EID: 15044357353     PISSN: 09288244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.femsim.2004.12.001     Document Type: Article

References (46)

1. B.M. Gray Pneumococcal infections in an era of multiple antibiotic resistance Adv. Pediatr. Infect. Dis. 11 1996 55 99
2. E.I. Tuomanen, R. Austrian, and H.R. Masure Pathogenesis of pneumococcal infection New Eng. J. Med. 332 1995 1280 1284
3. H. Kayhty, and J. Eskola New vaccines for the prevention of pneumococcal infections Emerg. Infect. Dis. 2 1996 289 298
4. D. Bogaert, P.W.M. Hermans, P.V. Adrian, H.C. Rümke, and R. de Groot Pneumococcal vaccines: an update on current strategies Vaccine 22 2004 2209 2220
5. M.C. McEllistrem, J. Adams, E.O. Mason, and E.R. Wald Epidemiology of acute otitis media caused by Streptococcus pneumoniae before and after licensure of the 7-valent pneumococcal protein conjugate vaccine J. Infect. Dis. 188 2003 1679 1684
6. M.J. Crain, W.D. Waltman II, J.S. Turner, J. Yother, D.F. Talkington, L.S. McDaniel, B.M. Gray, and D.E. Briles Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniae Infect. Immun. 1990 1990 3293 3299
7. D.F. Talkington, B.G. Brown, J.A. Tharpe, A. Koenig, and H. Russell Protection of mice against fatal pneumococcal challenge by immunization with pneumococcal surface adhesin A (psaA) Microbial Pathogen. 21 1996 17 22
8. R.A. Lock, J.C. Paton, and D. Hansman Comparative efficacy of pneumoccal neuranimidase and pneumolysin as immunogens protective against Streptococcus pneumoniae Microbial Pathogen. 5 1988 461 467
9. D.E. Briles, S.K. Hollingshead, J. King, A. Swift, P.A. Braun, M.K. Park, L.M. Ferguson, M.H. Nahm, and G.S. Nabors Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA J. Infect. Dis. 182 2000 1694 1701
10. R.J. Bongaerts, H.-P. Heinz, U. Hadding, and G. Zysk Antigenicity, expression, and molecular characterization of surface-located pullulanase of Streptococcus pneumoniae Infect. Immun. 68 2000 7141 7143
11. G. Zysk, R.J. Bongaerts, E. ten Thoren, G. Bethe, R. Hakenbeck, and H.P. Heinz Detection of 23 immunogenic pneumococcal proteins using convalescent-phase serum Infect. Immun. 68 2000 3740 3743
12. T.M. Wizemann, J.H. Heinrichs, J.E. Adamou, A.L. Erwin, C. Kunsch, G.H. Choi, S.C. Barash, C.A. Rosen, H.R. Masure, E. Tuomanen, A. Gayle, Y.A. Brewah, W. Walsh, P. Barren, R. Lathigra, M. Hanson, S. Langermann, S. Johnson, and S. Koenig Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection Infect. Immun. 69 2001 1593 1598
13. J. Hoskins, W.E. Alborn Jr., J. Arnold, L.C. Blaszczak, S. Burgett, B.S. DeHoff, S.T. Estrem, L. Fritz, D.J. Fu, W. Fuller, C. Geringer, R. Gilmour, J.S. Glass, H. Khoja, A.R. Kraft, R.E. Lagace, D.J. LeBlanc, L.N. Lee, E.J. Lefkowitz, J. Lu, P. Matsushima, S.M. McAhren, M. McHenney, K. McLeaster, C.W. Mundy, T.I. Nicas, F.H. Norris, M. O'Gara, R.B. Peery, G.T. Robertson, P. Rockey, P.M. Sun, M.E. Winkler, Y. Yang, M. Young-Bellido, G. Zhao, C.A. Zook, R.H. Baltz, S.R. Jaskunas, P.R. Rosteck Jr., P.L. Skatrud, and J.I. Glass Genome of the bacterium Streptococcus pneumoniae strain R6 J. Bacteriol. 183 2001 5709 5717
14. H. Tettelin, K.E. Nelson, I.T. Paulsen, J.A. Elsen, T.D. Read, S. Peterson, J. Heidelberg, R.T. DeBoy, D.H. Haft, R.J. Dodson, A.S. Durkin, M. Gwinn, J.F. Kolonay, W.C. Nelson, J.D. Peterson, L.A. Umayam, O. White, S.L. Salzberg, M.R. Lewis, D. Radune, E. Holtzapple, H. Khouri, A.M. Wolf, T.R. Utterback, C.L. Hansen, L.A. McDonald, T.V. Felbblyum, S. Angiuoli, T. Dickinson, E.K. Hickey, I.E. Holt, B.J. Loftus, F. Yang, H.O. Smith, J.C. Venter, B.A. Dougherty, D.A. Morrison, S.K. Hollingshead, and C.M. Fraser Complete genome sequence of a virulent isolate of Streptococcus pneumoniae Science 293 2001 498 506
15. R.A. Lock, J.C. Paton, and D. Hansman Purification and immunological characterization of neuraminidase produced by Streptococcus pneumoniae Microbial Pathogen. 4 1988 33 43
16. H. Suzuki, and T. Terada Removal of dodecyl sulfate from protein solution Anal. Biochem. 172 1988 259 263
17. J.M. Kyd, A. John, A.W. Cripps, and T.F. Murphy Investigation of mucosal immunisation in pulmonary clearance of Moraxella (Branhamella) catarrhalis Vaccine 18 2000 398 406
18. J. Kolberg, E.A. Høiby, R. Lopez, and K. Sletten Monoclonal antibodies against Streptococcus pneumoniae detect epitopes on eubacterial ribosomal proteins L7/L12 and on streptococcal elongation factor Ts Microbiology 143 1997 55 61
19. E.L. Nuermberger, and W.R. Bishai Antibiotic resistance in Streptococcus pneumoniae: what does the future hold? Clin. Infect.Dis. 38 Suppl. 4 2004 S363 S371
20. H.-Y. Lee, A. Andalibi, P. Webster, S.-K. Moon, K. Teufert, S.-H. Kang, J.-D. Li, M. Nagura, T. Ganz, and D.J. Lim Antimicrobial activity of innate immune molecules against Streptococcus pneumoniae, Moraxella catarrhalis and nontypeable Haemophilus influenzae BMC Infect. Dis. 4 2004 12
21. Mellon, G., Wilson, C., Hamilton, E., Silberberg, P., Munkara, M., Leach, A.J. and Morris, P.S. (2004) Impact of 7-valent pneumococcal conjugate vaccine on rates of tympanic membrane perforation in young aboriginal children living in remote communities throughout the Northern Territory of Australia: a before and after study. In: Proceedings of the 4th International Symposium on Pneumococci and Pneumococcal Disease, Helsinki, Finland PSV-37
22. Hare, K., Leach, A., Beissbarth, B., Stubbs, E., Mellon, G., Wilson, C. and Morris, P. (2004) Post-pneumococcal conjugate vaccine carriage and serotype distribution among young aboriginal children living in 29 remote communities in the Northern Territory of Australia. In: Proceedings of the 4th International Symposium on Pneumococci and Pneumococcal Disease, Helsinki, Finland PSV-23
23. WHO-position-paper (1999) Pneumococcal vaccines. Wkly. Epidemiol. Rec. 74, 177-184
24. S.I. Pelton, R. Dagan, B.M. Gaines, K.P. Klugman, D. Laufer, K.L. O'Brien, and H.J. Schmitt Pneumococcal conjugate vaccines: Proceedings from an Interactive Symposium at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy Vaccine 21 2003 1562 1571
25. R. Prymula, J. Motlova, and P. Kriz Comparison of Streptococcus pneumoniae serotypes causing acute otitis media and invasive disease in young children in the Czech Republic Indian J. Med. Res. 119 2004 168 170
26. W.P. Hausdorff, J. Bryant, P.R. Paradiso, and G.R. Siber Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use. Part I Clin. Infect. Dis. 30 2000 100 121
27. R. Veenhoven, D. Bogaert, C. Uiterwaal, C. Brouwer, H. Kiezebrink, J. Bruin, E. Uzerman, P. Hermans, R. de Groot, B. Zegers, W. Kuis, A. Schilder, and W. Sanders Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomised study Lancet 361 2003 2189 2195
28. J. Hamel, N. Charland, I. Pineau, C. Ouellet, S. Rioux, D. Martin, and B.R. Brodeur Prevention of pneumococcal disease in mice immunized with conserved surface-accessible proteins Infect. Immun. 72 2004 2659 2670
29. J.S. Brown, A.D. Ogunniyi, M.C. Woodrow, D.W. Holden, and J.C. Paton Immunization with components of two iron uptake ABC transporters protects mice against systemic Streptococcus pneumoniae infection Infect. Immun. 69 2001 6702 6706
30. Jomaa, M., Brown, J., Yuste, J. and Dougan, G. (2004) Immune response to immunisation with two iron uptake ABC transporter proteins, PiaA and PiuA. In: Proceedings of the 4th International Symposium on Pneumococci and Pneumococcal Disease, Helsinki, Finland PROT-16
31. Moore, Q., Bosarge, J. and McDaniel, L. (2004) Protection against pneumococcal infection by prime-boost immunisation with DNA and protein. In: Proceedings of the 4th International Symposium on Pneumococci and Pneumococcal Disease, Helsinki, Finland PROT-20
32. T. Itoh, and B. Wittmann-Liebold The primary structure of Bacillus subtilis acidic ribosomal protein B-L9 and its comparison with Escherichia coli proteins L7/L12 FEBS Lett. 96 1978 392 394
33. B. Modun, and P. Williams The staphylococcal transferrin-binding protein is a cell wall glyceraldehyde-3-phosphate dehydrogenase Infect. Immun. 67 1999 1086 1092
34. V. Pancholi, and V.A. Fischetti Glyceraldehyde-3-phosphate dehydrogenase on the surface of group A streptococci is also an ADP-ribosylating enzyme Proc. Natl. Acad. Sci. USA 90 1993 8154 8158
35. J. Kolberg, and K. Sletten Monoclonal antibodies that recognize a common pneumococcal protein with similarities to streptococcal group A surface glyceraldehyde-3-phosphate dehydrogenase Infect. Immun. 64 1996 3544 3547
36. V. Pancholi, and V.A. Fischetti A major surface protein on group A streptococci is a glyceraldehyde-3-phosphate-dehydrogenase with multiple binding activity J. Exp. Med. 176 1992 415 426
37. S. Romero-Streiner, D. Libutti, L.B. Pais, J. Dykes, P. Anderson, J.C. Whittin, H.L. Keyserling, and G.M. Carlone Standarization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells Clin Diagn. Lab. Immunol. 4 1997 415 422
38. J.E. Martinez, S. Romero-Steiner, T. Pilishvili, S. Barnard, J. Schinsky, D. Goldblatt, and G.M. Carlone A flow cytometric opsonophagocytic assay for measurement of functional antibodies elicited after vaccination with the 23-valent pneumococcal polysaccharide vaccine Clin. Diagn. Lab. Immunol. 6 1999 581 586
39. A. Finn, Q. Zhang, L. Seymour, C. Fasching, E. Pettitt, and E.N. Janoff Induction of functional secretory IgA responses in breast milk, by pneumococcal capsular polysaccharides J. Infect. Dis. 186 2002 1422 1429
40. A. Soininen, M. Karpala, S.-L. Wahlman, H. Lehtonen, and H. Kayhty Specificities and opsonophagocytic activities of antibodies to pneumococcal capsular polysaccharides in sera of unimmunized young children Clin. Diagn. Lab. Immunol. 9 2002 1032 1038
41. V. Pancholi, and V.A. Fischetti α-Enolase, a novel strong plasmin(ogen) binding protein on the surface of pathogenic Streptococci J. Biol. Chem. 273 1998 14503 14515
42. H.-Y. Wu, M.H. Nahm, Y. Guo, M.W. Russell, and D.E. Briles Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae J. Infect. Dis. 175 1997 839 846
43. Q. Zhang, S. Choo, and A. Finn Immune responses to novel pneumococcal proteins pneumolysin, PspA, PsaA, and CbpA in adenoidal B cells from children Infect. Immun. 70 2002 5363 5369
44. R. Service Triggering the first line of defence Science 265 1994 1522 1544
45. S. Rapola, V. Jantti, R. Haikala, R. Syrjanen, G.M. Carlone, J.S. Sampson, D.E. Briles, J.C. Paton, A.K. Takala, T.M. Kilpi, and H. Kayhty Natural development of antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A, and pneumolysin in relation to pneumococcal carriage and acute otitis media J. Infect. Dis. 182 2000 1146 1152
46. B. Simell, M. Korkeila, H. Pursiainen, T.M. Kilpi, and H. Kayhty Pneumococcal carriage and otitis media induce salivary antibodies to pneumococcal surface adhesion A, pneumolysin, and pneumococcal surface protein A in children J. Infect. Dis. 183 2001 887 896